Stock-Based Compensation

12 Months Ended

May 31, 2021

Share-based Payment Arrangement, Noncash Expense [Abstract]

On August 2, 2016, the Board of Directors approved and adopted the Cintas Corporation 2016 Equity and Incentive Compensation Plan (the 2016 Plan) to replace the Cintas' 2005 Equity Compensation Plan, as amended (the 2005 Plan). The 2016 Plan was approved by Cintas shareholders at its Annual Meeting on October 18, 2016, at which time the 2016 Plan became effective. Under the 2016 Plan, Cintas may grant officers and key employee-partners equity compensation in the form of stock options, stock appreciation rights, restricted and unrestricted stock awards, performance awards and other stock unit awards representing up to an aggregate of 12,500,000 shares of Cintas' common stock. Any shares of common stock that remained available under the 2005 Plan became part of the total available share balance of 12,500,000 shares under the 2016 Plan. At May 31, 2021, 6,358,437 shares of common stock were reserved for future issuance under the 2016 Plan. Total compensation cost for stock-based awards for continuing operations was $112.0 million, $115.4 million and $139.2 million for the fiscal years ended May 31, 2021, 2020 and 2019, respectively. Cintas accounts for forfeitures of stock-based awards as they occur. The total income tax benefit recognized in the consolidated statements of income for share-based compensation arrangements for continuing operations was $28.6 million, $29.2 million and $34.0 million for the fiscal years ended May 31, 2021, 2020 and 2019, respectively.

Stock Options

Stock options are granted at the fair market value of the underlying common stock on the date of grant. The option terms are determined by the Compensation Committee of the Board of Directors, but no stock option may be exercised later than 10 years after the date of the grant. The option awards generally have 10-year terms with graded vesting in years 3 through 5 based on continuous service during that period. Cintas recognizes compensation expense for these options using the straight-line recognition method over the vesting period.

The fair value of options was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions for the fiscal years ended May 31:


	2021		2020		2019

Risk-free interest rate	0.4	%	1.9	%	2.7	%
Dividend yield	1.1	%	1.1	%	1.2	%
Expected volatility of Cintas' common stock	23.5	%	19.0	%	17.9	%
Expected life of the option in years	5.5		6.0		6.0

The risk-free interest rate is based on U.S. government issues with a remaining term equal to the expected life of the stock options. The determination of expected volatility is based on historical volatility of Cintas' common stock over the period commensurate with the expected term of stock options, as well as other relevant factors. The weighted average expected term was determined based on the historical employee exercise behavior of the options. The weighted-average fair value of stock options granted during fiscal 2021, 2020 and 2019 was $66.52, $48.20 and $47.68, respectively.

The information presented in the following table relates primarily to stock options granted and outstanding under either the 2016 Plan or under previously adopted plans:


	Shares	Weighted Average Exercise Price

Outstanding, June 1, 2018 (2,006,922 shares exercisable)	8,930,186	$	96.71
Granted	1,013,005	219.37
Canceled	(3,045)	58.03
Forfeited	(397,304)	155.39
Exercised	(1,333,908)	54.14
Outstanding, May 31, 2019 (1,919,976 shares exercisable)	8,208,934	123.80
Granted	575,813	250.50
Canceled	(5,432)	72.17
Forfeited	(312,391)	185.08
Exercised	(1,361,525)	70.03
Outstanding, May 31, 2020 (1,913,374 shares exercisable)	7,105,399	145.54
Granted	747,550	348.24
Canceled	(1,452)	59.51
Forfeited	(91,722)	193.94
Exercised	(1,704,251)	83.31
Outstanding, May 31, 2021 (1,548,867 shares exercisable)	6,055,524	$	191.11

The intrinsic value of stock options exercised was $402.3 million, $262.1 million and $193.6 million for the fiscal years ended May 31, 2021, 2020 and 2019, respectively. The total cash received from employees as a result of employee stock option exercises for the fiscal years ended May 31, 2021, 2020 and 2019 was $130.0 million, $90.5 million and $65.4 million, respectively.

The fair value of stock options vested was $30.5 million, $27.8 million and $22.4 million for the fiscal years ended May 31, 2021, 2020 and 2019, respectively.

The following table summarizes the information related to stock options outstanding at May 31, 2021:


		Outstanding Options			Exercisable Options
Range of Exercise Prices	Number Outstanding	Average Remaining Option Life	Weighted Average Exercise Price		Number Exercisable	Weighted Average Exercise Price
$28.14 - $108.39	1,621,375	3.93	$	83.28	1,248,866	$	75.94
$108.40 - $204.48	1,329,236	6.30	143.30		280,610	137.55
$204.49 - $260.79	1,865,666	7.58	228.36		6,752	230.79
$260.80 - $361.09	1,239,247	9.61	327.37		12,639	277.33
$28.14 - $361.09	6,055,524	6.74	$	191.11	1,548,867	$	89.42

At May 31, 2021, the aggregate intrinsic value of stock options outstanding and exercisable was $983.6 million and $409.1 million, respectively. The weighted-average remaining contractual term of stock options exercisable is 4.1 years.

Restricted Stock Awards

Restricted stock awards consist of Cintas' common stock that is subject to such conditions, restrictions and limitations as the Compensation Committee of the Board of Directors determines to be appropriate. The vesting period is generally three years after the grant date. The recipient of restricted stock awards will have all rights of a shareholder of Cintas, including the right to vote and the right to receive cash dividends during the vesting period. Cintas recognizes compensation expense for these restricted stock awards using the straight-line recognition method over the vesting period.

The information presented in the following table relates to restricted stock awards granted and outstanding under either the 2016 Plan or under previously adopted plans:


	Shares	Weighted Average Grant Price

Outstanding, unvested grants at June 1, 2018	2,641,114	$	122.18
Granted	425,614	221.27
Forfeited	(109,393)	169.48
Vested	(765,647)	93.37
Outstanding, unvested grants at May 31, 2019	2,191,688	149.12
Granted	228,292	248.39
Forfeited	(135,934)	208.37
Vested	(658,831)	113.93
Outstanding, unvested grants at May 31, 2020	1,625,215	199.73
Granted	274,843	352.68
Forfeited	(48,586)	241.95
Vested	(610,249)	147.32
Outstanding, unvested grants at May 31, 2021	1,241,223	$	264.63

The remaining unrecognized compensation cost related to unvested stock options and restricted stock at May 31, 2021 was $224.0 million. The weighted-average period of time over which this cost will be recognized is 1.98 years.